← Back to Screener
MBX Biosciences, Inc. Common Stock (MBX)
Price$33.22
Favorite Metrics
Price vs S&P 500 (26W)103.83%
Price vs S&P 500 (4W)9.02%
Market Capitalization$1.57B
All Metrics
Book Value / Share (Quarterly)$8.22
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.82
Price vs S&P 500 (YTD)1.86%
EPS (TTM)$-2.42
10-Day Avg Trading Volume0.50M
EPS Excl Extra (TTM)$-2.42
EPS (Annual)$-2.38
ROI (Annual)-23.56%
Cash / Share (Quarterly)$8.32
ROA (Last FY)-22.58%
EBITD / Share (TTM)$-2.68
Cash Flow / Share (Annual)$-1.82
P/B Ratio4.24x
P/B Ratio (Quarterly)3.84x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-347.47x
ROA (TTM)-27.55%
EPS Incl Extra (Annual)$-2.38
Current Ratio (Annual)24.62x
Quick Ratio (Quarterly)24.31x
3-Month Avg Trading Volume0.67M
52-Week Price Return343.61%
Revenue / Employee (TTM)$0
52-Week High$44.89
EPS Excl Extra (Annual)$-2.38
26-Week Price Return107.82%
Quick Ratio (Annual)24.31x
13-Week Price Return-9.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)24.62x
Enterprise Value$1,490.649
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.32
3-Month Return Std Dev85.53%
Net Income / Employee (TTM)$-1
ROE (Last FY)-23.56%
EPS Basic Excl Extra (Annual)$-2.38
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.42
ROI (TTM)-28.72%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)313.78%
Year-to-Date Return4.50%
5-Day Price Return0.30%
EPS Normalized (Annual)$-2.38
Month-to-Date Return10.42%
EBITD / Share (Annual)$-2.68
EPS Basic Excl Extra (TTM)$-2.42
P/B Ratio (Annual)3.84x
Book Value / Share (Annual)$8.22
Price vs S&P 500 (13W)-10.31%
Beta1.62x
Revenue / Share (TTM)$0.00
ROE (TTM)-28.72%
52-Week Low$6.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | — | — | — | — | $33.22 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary PEP platform optimizes pharmaceutical properties including extended duration, consistent drug exposure, and reduced dosing frequency compared to conventional peptides. The company's pipeline includes three candidates: MBX 2109, MBX 1416, and MBX 4291.